The public needs better understanding of drug regulationBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7548.990-a (Published 27 April 2006) Cite this as: BMJ 2006;332:990
- Susan Mayor1
- 1 London
Healthcare professionals and patients should be given more information on how new drugs are licensed, to avoid confusion like that surrounding access to trastuzumab (Herceptin) for women with early breast cancer, medicines policy experts have suggested.
Trastuzumab is currently licensed only in New Zealand for early breast cancer that is HER2 receptive, with licence applications for this indication currently being considered by European, US, and Australian drug regulators.
However, an investor …
Log in using your username and password
Log in through your institution
Sign up for a free trial